We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

6841:TSEYokogawa Electric Corp. Analysis

Data as of 2026-03-14 - not real-time

NT$58.90

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Ever Fortune.AI is trading at TWD 58.9, well below its 20‑day SMA of 63.2 and 50‑day SMA of 66.1, indicating a bearish price gap. The 14‑day RSI sits at 36.5, suggesting lingering weakness but not yet oversold. MACD is in a bearish configuration with the line below the signal and a negative histogram, confirming downward momentum. Volume has been decreasing, and the stock is hovering just above the technical support of TWD 57.4, leaving limited upside before hitting the nearest resistance at TWD 73. Volatility is elevated at 44 % over the past 30 days, and beta of 0.56 points to modest market sensitivity but high idiosyncratic risk. On the valuation side, the trailing P/E of 50.3 dwarfs the industry average of 26.2, and the DCF‑derived fair value of TWD 8.8 implies the market price is over 600 % above intrinsic estimates.
Fundamentals are mixed: revenue has contracted 14.7 % YoY, operating margin is negative, and free cash flow is –TWD 59.3 M, raising concerns about cash‑flow sustainability. The company carries a modest debt load (D/E 0.37) and a strong cash pile of TWD 658 M, yet the high payout ratio of 87 % on a 1.74 % dividend yield questions dividend durability. Recent news notes a price‑to‑book rise to 3.7×, up 8.8 % YoY, reflecting continued market enthusiasm despite deteriorating earnings. The business operates in the health‑information services niche, where regulatory scrutiny is high and Chinese market exposure adds geopolitical risk. Given the overvalued status, weak cash generation, and bearish technical signals, the near‑term outlook is constrained, though the AI‑driven product pipeline could offer medium‑term upside if profitability improves. Investors should therefore treat the stock as a high‑risk, overvalued play, with any upside contingent on a turnaround in margins and cash flow.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Bearish technical indicators (price below SMAs, MACD negative)
  • Significant overvaluation relative to fair value
  • Weak cash flow and negative free cash flow

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential upside from AI-driven healthcare products
  • Strong cash reserves despite cash‑flow deficits
  • High dividend payout may become unsustainable

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Long‑term growth opportunity in medical AI market
  • Continued regulatory and geopolitical exposure
  • Current valuation gap requires earnings turnaround

Key Metrics & Analysis

Financial Health

Revenue Growth-14.70%
Profit Margin32.54%
P/E Ratio50.3
ROE7.01%
ROA0.75%
Debt/Equity0.37
P/B Ratio3.3
Op. Cash FlowNT$18.8M
Free Cash FlowNT$-59293000
Industry P/E26.2

Technical Analysis

TrendBearish
RSI36.5
SupportNT$57.40
ResistanceNT$73.00
MA 20NT$63.18
MA 50NT$66.10
MA 200NT$68.11
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair ValueNT$8.78
Target PriceNT$104.00
Upside/Downside76.57%
GradeOvervalued
TypeBlend
Dividend Yield1.74%

Risk Assessment

Beta0.56
Volatility44.20%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.